Mar 28, 2022
ACTON, Mass. , March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced...
Mar 24, 2022
ACTON, Mass. , March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced...
Mar 10, 2022
Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 2021 ended with approximately $19 million in cash expected to fund operations beyond the date of our anticipated regulatory approval and initial...
Jan 31, 2022
ACTON, Mass. , Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced...
Jan 13, 2022
This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives ACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue...
Jan 05, 2022
ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the...
Dec 16, 2021
IL-6 test for sepsis triage on Track for January 2022 FDA Pre-Submission Filing Expanded Testing Program Planned for Q1-Q3 2022 Raised $21.6 million Gross Proceeds in an Upsized IPO ACTON, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc....
Nov 10, 2021
ACTON, Mass. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage, diagnosis and monitoring of disease progression, today...
Jul 20, 2021
Bluejay Diagnostics, Inc. (the “Company”), announced today that Mr. Fred S. Zeidman has been appointed to the Boards of Directors and Chairman of Nominating and Corporate Governance Committee of the Company....
Dec 14, 2020
Acton, MA, Dec 8, 2020 – Bluejay Diagnostics, Inc. (Bluejay, Acton, MA) today announced a collaboration agreement with Toray Industries, Inc. (Toray, Tokyo, Japan) to develop a minimally-invasive, point-of-care test for COVID-19 patients to assess progression of the disease....